Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier

Development of optimized self-nano-emulsifying drug delivery systems (SNEDDS) of carvedilol with enhanced bioavailability potential

(2011) Bhupinder Singh et al.   DRUG DELIVERY

A Novel Approach for Predicting P-Glycoprotein (ABCB1) Inhibition Using Molecular Interaction Fields

(2011) Fabio Broccatelli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice

(2010) Katrin M. Kirschbaum et al.   NEUROPHARMACOLOGY

Single- and Multiple-Dose Pharmacokinetics and Dose Proportionality of the Psychotropic Agent Paliperidone Extended Release

(2009) Sandra Boom et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Drug interactions at the blood-brain barrier: Fact or fantasy?☆

(2009) Sara Eyal et al.   PHARMACOLOGY & THERAPEUTICS

Aripiprazole brain concentration is altered in P-glycoprotein deficient mice

(2009) Jun-Sheng Wang et al.   SCHIZOPHRENIA RESEARCH

Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein

(2009) T. Tachibana et al.   XENOBIOTICA

Antipsychotic Drugs Inhibit the Function of Breast Cancer Resistance Protein

(2008) Jun-Sheng Wang et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Drug–Drug Interactions Mediated Through P-Glycoprotein: Clinical Relevance and In Vitro–In Vivo Correlation Using Digoxin as a Probe Drug

(2008) KS Fenner et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Metabolism of Atypical Antipsychotics: Involvement of Cytochrome P450 Enzymes and Relevance for Drug-Drug Interactions

(2008) Liana Urichuk et al.   CURRENT DRUG METABOLISM

Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4)

(2008) A. Ose et al.   DRUG METABOLISM AND DISPOSITION